Dr Reddy's receives two USFDA observations for New York API facility
Dr. Reddy's Laboratories faced USFDA scrutiny at its New York API facility, receiving a Form 483 with two observations after a GMP inspection concluded on May 16, 2025. The company will address these concerns within the given timeframe.
Dr. Reddy's Laboratories faced USFDA scrutiny at its New York API facility, receiving a Form 483 with two observations after a GMP inspection concluded on May 16, 2025. The company will address these concerns within the given timeframe.
